Coherus Oncology, Inc. CHRS
Updated: 12 Aug 2026
No signal published yet
We already track Coherus Oncology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Coherus Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Coherus Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Coherus Oncology reported its second-quarter 2026 financial results, with LOQTORZI net revenue rising 37% year-over-year to $13.6 million. Net loss from continuing operations narrowed to $33.3 million compared to $44.9 million in the prior-year period. The company ended the second quarter with $105.3 million in cash, cash equivalents, and marketable securities.
What Firelda Watch includes for Coherus Oncology, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Coherus Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Coherus Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more